Digbi Health Introduces Industry-First Medically Managed Weight Loss Program That Leverages Precision Biology to Improve GLP-1 Drug Effectiveness, Adherence, and Tapering
The program combines genetic insights, gut microbiome analysis and continuous glucose monitoring to improve GLP-1 outcomes and support successful medication tapering.
PALO ALTO, Calif., September 24, 2024 /Digbi Newswire/ -- Digbi Health expands its award-winning multi-condition telehealth platform with the introduction of a comprehensive solution that leverages genetic insights, gut microbiome analysis and continuous glucose monitors to improve the effectiveness of GLP-1 drugs and support successful medication tapering.
Key features of the medically managed program
- Comprehensive GI health screening and care — The program offers in-depth GI clinical assessments, tracking, and at-home gut microbiome testing to address the GI adverse effects that impact the adherence and effectiveness of GLP-1s.
- Personalized treatment — Digbi uses GLP-Fit™ to determine the best treatment path and delivers care personalized to the individual.
- Real-time nutritional guidance — The program provides AI-supported nutritional guidance to improve muscle and glucose health.
- Convenience and adaptability — Patients can work with their existing physicians or access Digbi Health's telehealth platform for GLP-1 prescriptions.
Originally distributed via Business Wire.
About Digbi Health
Digbi Health is the precision biology care company unifying metabolic and inflammatory care — including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan — partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans.
SOURCE Digbi Health
- GLP-1
- Tapering
- Telehealth
- Gut Microbiome
- Precision Biology